Association between chemotherapy and cognitive impairments in a large cohort of patients with colorectal cancer

International Journal of Oncology

Volumn 42, Issue 6, 2013, Pages 2123-2133

  Du, Xianglin L ^a   Cai, Yi ^a   Symanski, Elaine ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Chemotherapy; Cognitive impairments; Colorectal cancer; Dementia; Elderly people

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER SIZE; CANCER STAGING; COGNITIVE DEFECT; COHORT ANALYSIS; COLORECTAL CANCER; COMORBIDITY; CONTROLLED STUDY; DEMENTIA; DRUG INDUCED DISEASE; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MULTIINFARCT DEMENTIA; PRIMARY TUMOR; PRIORITY JOURNAL; PSYCHOSIS; SOCIAL STATUS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COGNITION DISORDERS; COHORT STUDIES; COLORECTAL NEOPLASMS; DEMENTIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; SEER PROGRAM;

EID: 84876572506     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1882     Document Type: Article

References (61)

1. NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 264: 1444-1450, 1990.
2. Moertel CG, Fleming TR, Macdonald JS, et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a fnal report. Ann Intern Med 122: 321-326, 1995.
3. Sargent DJ, Goldberg RM, Jacobson SD, et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345: 1091-1097, 2001.
4. Gill S, Loprinzi CL, Sargent DJ, et al: Pooled analysis of fuoro-uracil-based adjuvant therapy for stage II and III colon cancer: who benefts and by how much? J Clin Oncol 22: 1797-1806, 2004. (Pubitemid 41095169)
5. National Cancer Institute: Colon and Rectal cancer Treatment. http://www.cancer.gov/cancertopics/treatment/colon-and-rectal. Accessed September 16, 2012.
6. O'Connell MJ, Martenson JA, Wieand HS, et al: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fuorouracil with radiation therapy after curative surgery. N Engl J Med 331: 502-507, 1994.
7. Figueredo A, Charette ML, Maroun J, Brouwers MC and Zuraw L: Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 22: 3395-3407, 2004. (Pubitemid 41103699)
8. Benson AB III, Schrag D, Somerfield MR, et al: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22: 3408-3419, 2004. (Pubitemid 41103700)
9. Sargent DJ, Wieand HS, Haller DG, et al: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20, 898 patients on 18 randomized trials. J Clin Oncol 23: 8664-8670, 2005. (Pubitemid 46211509)
10. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al: Pooled analysis of safety and effcacy of oxaliplatin plus fuorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24: 4085-4091, 2006. (Pubitemid 46622283)
11. André T, Boni C, Navarro M, et al: Improved overall survival with oxaliplatin, fuorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27: 3109-3116, 2009.
12. Schrag D, Rifas-Shiman S, Saltz L, Bach PB and Begg CB: Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 20: 3999-4005, 2002.
13. O'Connor ES, Greenblatt DY, LoConte NK, et al: Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 29: 3381-3388, 2011.
14. Silberfarb PM, Philibert D and Levine PM: Psychosocial aspects of neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer patients. Am J Psychiatry 137: 597-601, 1980. (Pubitemid 10107447)
15. Oxman TE and Silberfarb PM: Serial cognitive testing in cancer patients receiving chemotherapy. Am J Psychiatry 137: 1263-1265, 1980. (Pubitemid 10015087)
16. Devlen J, Maguire P, Phillips P and Crowther D: Psychological problems associated with diagnosis and treatment of lymphomas. II: Prospective study. Br Med J 295: 955-957, 1987.
17. Parth P, Dunlap W P, Kennedy RS, et al: Motor and cognitive testing of bone marrow transplant patients after chemoradio-therapy. Percept Mot Skills 68: 1227-1241, 1989.
18. Copeland DR, Moore BD III, Francis DJ, et al: Neuropsy-chologic effects of chemotherapy on children with cancer: a longitudinal study. J Clin Oncol 14: 2826-2835, 1996. (Pubitemid 26329670)
19. Waber DP, Tarbell NJ, Fairclough D, et al: Cognitive sequelae of treatment in childhood acute lymphoblastic leukemia: cranial radiation requires an accomplice. J Clin Oncol 13: 2490-2496, 1995.
20. Ahles TA, Silberfarb PM, Rundle AC, et al: Quality of life in patients with limited small-cell carcinoma of the lung receiving chemotherapy with or without radiation therapy, for cancer and Leukemia Group B. Psychother Psychosom 62: 193-199, 1994. (Pubitemid 24322759)
21. Wieneke MH and Dienst ER: Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology 4: 61-66, 1995. (Pubitemid 26093776)
22. Meyers CA, Byrne KS and Komaki R: Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer 12: 231-235, 1995.
23. Schwartz CL: Late effects of treatment in long-term survivors of cancer. Cancer Treat Rev 21: 355-366, 1995.
24. van Dam FS, Schagen SB, Muller MJ, et al: Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90: 210-218, 1998. (Pubitemid 28114539)
25. Schagen SB, van Dam FS, Muller MJ, et al: Cognitive defcits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85: 640-650, 1999. (Pubitemid 29075285)
26. Schagen SB, Hamburger HL, Muller MJ, et al: Neu rop hysiolog i ca l evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol 51: 159-165, 2001. (Pubitemid 32435496)
27. Schagen SB, Muller MJ, Boogerd W, et al: Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 98: 1742-1745, 2006. (Pubitemid 44942713)
28. Kreukels BP, van Dam FS, Ridderinkhof KR, et al: Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer. Clin Breast Cancer 8: 80-87, 2008. (Pubitemid 351346233)
29. Brezden CB, Phillips KA, Abdolell M, et al: Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18: 2695-2701, 2000. (Pubitemid 30463551)
30. Wefel JS, Lenzi R, Theriault RL, Davis RN and Meyers CA: The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100: 2292-2299, 2004. (Pubitemid 38657875)
31. Hurria A, Rosen C, Hudis C, et al: Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc 54: 925-931, 2006. (Pubitemid 43847029)
32. Deprez S, Amant F, Smeets A, et al: Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol 30: 274-281, 2012.
33. Heck JE, Albert SM, Franco R and Gorin SS: Patterns of dementia diagnosis in surveillance, epidemiology, and end results breast cancer survivors who use chemotherapy. J Am Geriatr Soc 56: 1687-1692, 2008.
34. Baxter NN, Durham SB, Phillips KA, Habermann EB and Virning BA: Risk of dementia in older breast cancer survivors: a population-based cohort study of the association with adjuvant chemotherapy. J Am Geriatr Soc 57: 403-411, 2009.
35. Raji MA, Tamborello L P, Kuo YF, Ju H, Freeman JL, Zhang DD, Giordano SH and Goodwin JS: Risk of subsequent dementia diagnoses does not vary by types of adjuvant chemotherapy in older women with breast cancer. Med Oncol 26: 452-459, 2009.
36. Du XL, Xia R and Hardy D: Relationship between chemotherapy use and cognitive impairments in older women with breast cancer: fndings from a large population-based cohort. Am J Clin Oncol 33: 533-543, 2010.
37. National Cancer Institute: About the SEER (Surveillance Epidemiology and End Results) Registries. http://seer.cancer.gov/registries/. Accessed September 15, 2012.
38. Warren JL, Klabunde CN, Schrag D, Bach PB and Riley GF: Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40 (Suppl): 3-18, 2002.
39. Parsons LS: Reducing Bias in a Propensity Score Matching-Pair Sample Using Greedy Matching Techniques, available at http://www2.sas.com/proceedings/ sugi26/p214-26.pdf. Accessed July 2, 2012.
40. Du XL and Goodwin JS: Patterns of use of chemotherapy for breast cancer in older women: fndings from Medicare claims data. J Clin Oncol 19: 1455-1461, 2001. (Pubitemid 32202553)
41. Warren JL, Harlan LC, Fahey A, et al: Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 40: IV-55-IV-61, 2002.
42. Du XL, Key CR, Dickie L, et al: External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews. Med Care 44: 124-131, 2006. (Pubitemid 43755463)
43. Lamont EB, Herndon JE II, Weeks JC, et al: Criterion validity of Medicare chemotherapy claims in cancer and leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst 97: 1080-1083, 2005. (Pubitemid 41417925)
44. Liang SY, Phillips KA, Wang G, et al: Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer. Med Care 49: e1-e8, 2011.
45. Lund JL, Stürmer T, Harlan LC, et al: Identifying specific chemotherapeutic agents in medicare data: a validation study. Med Care: Nov 10, 2011 (Epub ahead of print).
46. US Public Health Services: International Classification of Diseases, 9th Revision, Clinical Modification. 5th edition. Practice Management Information Corp., Los Angeles, CA, 1996.
47. American Medical Association: Physicians' Current Procedural Terminology-CPT 2000. American Medical Association, Chicago, IL, 2000.
48. Health Care Financing Administration: HCFA Common Procedure Coding System: National Level II Medicare Codes. Practice Management Information Corp., Los Angeles, CA, 2000.
49. Charlson ME, Pompei P, Ales KL and MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373-383, 1987. (Pubitemid 17055592)
50. Romano PS, Roos LL and Jollis JG: Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 46: 1075-1079, 1993.
51. Klabunde CN, Potosky AL, Legler JM and Warren JL: Development of a comorbidity index using physician claims data. J Clin Epidemiol 53: 1258-1267, 2000. (Pubitemid 32007842)
52. National Cancer Institute. SEER-Medicare: Calculation of Comorbidity Weights. http://healthservices.cancer.gov/seermedi-care/program/comorbidity. html. Accessed July 18, 2012.
53. Penman AD and Johnson WD: A SAS program for calculating cumulative incidence of events (with confidence limits) and number at risk at specifed time intervals with partially censored data. Comput Methods Programs Biomed 89: 50-55, 2008. (Pubitemid 350296391)
54. Allison PD: Survival Analysis Using the SAS System: A Practical Guide. SAS Institute Inc., Cary, NC, 1995.
55. Ahles TA and Saykin AJ: Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 7: 192-201, 2007.
56. Long JM, Lee GD, Kelley-Bell B, Spangler EL, Perez EJ, Longo DL, de Cabo R, Zou S and Rapp PR: Preserved learning and memory following 5-fuorouracil and cyclophosphamide treatment in rats. Pharmacol Biochem Behav 100: 205-211, 2011.
57. Fremouw T, Fessler CL, Ferguson RJ and Burguete Y: Preserved learning and memory in mice following chemotherapy: 5-fuorouracil and doxorubicin single agent treatment, doxoru-bicin-cyclophosphamide combination treatment. Behav Brain Res 226: 154-162, 2012.
58. Fardell JE, Vardy J, Shah JD and Johnston IN: Cognitive impairments caused by oxaliplatin and 5-fuorouracil chemotherapy are ameliorated by physical activity. Psychopharmacology 220: 183-193, 2012.
59. Christie LA, Acharya MM, Parihar VK, Nguyen A, Martirosian V and Limoli CL: Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy. Clin Cancer Res 18: 1954-1965, 2012.
60. Winocur G, Henkelman M, Wojtowicz JM, Zhang H, Binns MA and Tannock IF: The effects of chemotherapy on cognitive function in a mouse model: a prospective study. Clin Cancer Res 18: 3112-3121, 2012.
61. Byers AL and Yaffe K: Depression and risk of developing dementia. Nat Rev Neurol 7: 323-331, 2011.